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Abstract: Adherence to antiretroviral therapy (ART) is critical for successful treatment of Human
Immunodeficiency Virus (HIV), but comparisons across settings are difficult because adherence is
measured in different ways. We examined utility of different adherence measures for identification
of patients at risk of viral failure (VF). Eight cohorts in the ART Cohort Collaboration contributed
data from pharmacy refills or self-report questionnaires collected between 1996 and 2013 (N = 11689).
For pharmacy data (N = 7156), we examined associations of percentage adherence during the 1st
year of ART with VF (>500 copies/mL) at 1 year. For self-report data (N = 4533), we examined
28-day adherence with VF based on closest viral load measure within 6 months after questionnaire
date. Since adherence differed markedly by measurement type, we defined different cut-off points
for pharmacy (lower <45%, medium 45–99%, higher 100%) and self-report (lower ≤95%, medium
96–99%, higher 100%) data. Adjusted odds ratios (ORs) for VF in lower and medium, compared
to higher adherence groups, were 23.04 (95% CI: 18.44–28.78) and 3.84 (3.36–4.39) for pharmacy
data. For self-report data, they were 3.19 (2.31–4.40) and 1.08 (0.80–1.46). Both types of measure
were strongly associated with VF. Although adherence measurements over longer time-frames are
preferable for prediction, they are less useful for intervention.
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1. Introduction
Adherence to antiretroviral therapy (ART) sufficient to suppress viral replication is critical for
successful treatment of HIV [1–5]. Traditionally, it has been suggested that patients should be at least
95% adherent to optimise virologic outcomes [6]. However, this threshold may not apply to new ART
regimens requiring less frequent dosing. Better-defining the relationship between adherence and viral
suppression could enable early identification of patients with problematic levels of adherence and,
hence, facilitate proactive interventions to prevent treatment failure.
Methods to assess medication adherence include self-report questionnaires, pharmacy-refill data,
pill counts, electronic drug monitoring, and monitoring drug levels in the blood [7,8]. However, research
findings can depend on which of these methods is used. The most commonly used adherence measures
are based on pharmacy-refill data or self-report questionnaires: their advantages and disadvantages have
been discussed extensively. Adherence derived using self-report questionnaires may be overestimated
because of the tendency for patients to provide perceived desirable answers [9], but self-report provides
an easy and fast way to measure adherence. Adherence estimated from pharmacy-refill data is likely
to be more objective and accurate than self-report, but requires protocols for data collection and
management [10]. Different measurement and calculation methods used on pharmacy data can lead to
inconsistencies [11,12] when data are compared across cohorts or used in pooled analyses.
We examined whether different adherence measures can be calibrated for use in pooled analyses by
using different cut-off points. In an era of large international HIV cohort collaborations, the appropriate
use of data combined from different settings is ever more important. Identifying those at risk of viral
failure is crucial for successful treatment, and so we also investigated the utility of different adherence
measures for identifying those at risk of viral failure, among cohorts participating in the ART Cohort
Collaboration (ART-CC).
2. Methods
2.1. Cohorts and Patients
ART-CC is a collaboration of cohort studies from Europe and North America established with the
aim of describing the prognosis of antiretroviral-naïve patients starting ART [13] (www.bris.ac.uk/art-cc).
Prospective cohort studies were eligible if they enrolled at least 100 HIV-1-positive ART-naïve patients
aged ≥16 years who started ART on at least three drugs, including nucleoside reverse-transcriptase
inhibitors (NRTIs), protease inhibitors (PIs), or non-nucleoside reverse-transcriptase inhibitors (NNRTIs),
with a median follow-up of at least 1 year. All cohorts use quality control procedures and provided a
predefined and anonymised set of demographic, laboratory, and clinical variables.
Eight cohorts, whose patients were enrolled in differing healthcare systems (see Table 1),
contributed adherence data, which were collected between 1996 and 2013: Italian Cohort of
Antiretroviral-Naïve Patients (ICONA) [14], the Swiss HIV Cohort Study (SHCS) [15], the HAART
Observational Medical Evaluation and Research (HOMER) [16] and the Southern Alberta Clinic
Cohort (Alberta) (Canada), the 1917 Clinic Cohort University of Alabama (UAB), the University
of Washington HIV Cohort (UW), the Veterans Affairs Cohort Study (VACS), and the HIV Atlanta
Veterans Affairs Cohort Study (HAVACS) (USA). The database was updated in September 2013.
Institutional review boards approved data collection at all sites, and each individual cohort has their
own separate approvals. Data from ICONA and SHCS were pooled in September 2013 within COHERE
in EuroCoord (www.cohere.org and www.EuroCoord.net). The NHS Health Research Authority South
West—Cornwall and Plymouth Research Ethics Committee, UK, has approved the ART-CC study
(REC reference 12/SW/0253).
2.2. Deriving Measures of Adherence and Viral Suppression
Four cohorts provided adherence data from pharmacy refills (Alberta, HOMER, VACS,
and HAVACS) and four from self-report questionnaires (ICONA, UAB, Washington, and SHCS).
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Only the VACS cohort provided data from both pharmacy refills and self-report questionnaires.
Adherence data were available for only a subset of the patients in ICONA, SHCS, UAB, UW, and
HAVACS as either, not all patients consented, or they spoke a different language or answered
a different version of the adherence question, which was not comparable as there was too little
discrimination (for example, one of the questions asked was “When was the last time you missed
any of your antiretrovirals?” Yesterday, Within the past week, 1–2 weeks ago, 3–4 weeks ago, Never
skip medications). However, the choice of these subsets should not have introduced bias as patient
characteristics in the analysis sample were similar to those of included patients from the same cohort.
Adherence data were available for all patients in Alberta, HOMER, and VACS.
Self-report questionnaires asked about behaviour in the last 28 days, and were administered
when patients attended clinical visits. For ICONA, UAB, and UW, patients were asked how often
they took their antiretrovirals in the last 28 days (month for ICONA), and asked to mark it on a
visual analogue scale ranging from 0 (never) to 100 (always). We used this as the percentage adherent.
For SHCS, the percentage adherence over the last 4 weeks was calculated based on patient-reported
number of missed doses. Questionnaires were administered multiple times, but at infrequent intervals.
In SHCS, the median time between questionnaires was 5 months, UW 7.5 months, ICONA 6.5 months,
UAB 6 months. Viral suppression (≤500 copies/mL) was based on the closest viral load measure
within 6 months after the questionnaire date (Figure 1).J. Clin. Med. 2018, 7, x FOR PEER REVIEW  4 of 15 
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Figure 1. Data timelines. For prescription measures, there was a median of −1 day between adherence
and viral load measure and, for self-report, a median of 84 days.
Pharmacy refill data record the date that a prescription was filled and how many days’ worth of
drug was supplied. From this, we know when a patient should return for another refill. For pharmacy
data, we derived 1-year percentage adherence and corresponding viral suppression (≤500 copies/mL)
based on the viral load closest to (and within± 3 months of) the 1-year time point (Figure 1). Percentage
adherence in the first year was derived as the number of days’ worth of drug supplied, divided by the
number of d ys on w ich the patient could have taken rugs. For most patients, the de ominator was
365 days, but it was less if they d ed, moved out f the a ea, or were advised to nterrupt reatment.
Patients were only inclu ed if they ha the potential for at least 1 year of pharmacy data (i.e., patients
with only 6 months of data bef r the dat base cl se date were not included). The method for
calculating the numerator for this ratio differed between cohorts. In HOMER, if a pat ent obtained their
next pres ription before their current ne h d run out, then this extra days’ supply was not included
in the numerator. If any individual drug was stopped a d started again with a gap of 30 days or less,
then this was assumed to be a continuous interval of drug supply because patients could be using up
those extra days’ supply (stockpiled medications). In Alberta, VACS, and HAVACS, if a patient returns
early for their refill, then the days covered for that refill do not start until the first prescription has run
out. This is described by the algorithm reported by Steiner et al. [12].
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2.3. Analysis
Patients were only included in the analysis if they had data on both adherence and viral load.
Median levels of adherence were compared between patients who were and were not suppressed.
We fitted receiver operating characteristic (ROC) curves (plots of (1-specificity) against sensitivity) to
assess the relationship between percentage adherence and viral suppression, separately in each cohort.
The area under the ROC curve (AUROC) was used to measure the discrimination of the adherence
measure for viral suppression: an AUROC of 0.5 corresponds to discrimination no better than expected
by chance, and 1 to perfect discrimination.
Logistic regression was used to examine associations of percentage adherence with viral
suppression. As a first step, adherence was categorised as <95% and ≥95%, because this is a widely
used classification. However, for self-report data, this categorisation had little meaning as most patients
rated their adherence to be very high. After examining the distribution of adherence among cohorts
with self-report and pharmacy data, we categorised adherence differently for cohorts with pharmacy
data (as <45% (low adherence), 45–99% (medium), and 100% (high)) and for cohorts with self-report
data (as ≤95% (low adherence), 96–99% (medium), and 100% (high)). These cut-offs were chosen to
make proportions as similar as possible across the pharmacy and self-report data. We fitted crude and
adjusted (for cohort, age, gender, CD4, and viral load at ART start, AIDS at ART start, and transmission
risk group) logistic regression models to assess the association of adherence with viral suppression.
StataTM version 13.0 [17] was used for all analyses.
2.4. Sensitivity Analyses
We considered whether the effect of adherence on suppression was modified by age,
and conducted sensitivity analyses (1) using a viral load cut-off of 50 copies/mL to define viral
suppression; (2) restricted to the most recent 5 years of data (2009–2013) in order to report on regimens
which are currently prescribed; and (3) restricted to patients who were still on their baseline ART
regimen at the time of the outcome measure. The different time frames used for pharmacy and
self-report adherence measures led us to consider using different time frames (3 and 6 months) for
pharmacy data, which could be more easily compared with self-report.
There has been discussion in the field of adherence to diabetes medication that patients who are
“over-adherent” (those who stockpile their medications and so appear to have >100% adherence) may be
different from the rest of the population [18,19]. We were able to assess whether patients from the Alberta,
VACS, and HAVACS cohorts were over-adherent, and ran a sensitivity analysis excluding those patients.
The VACS cohort had both pharmacy and self-report measures available for direct comparison
between the two methods. As the pharmacy measure is based on a 12-month period, we used the
question “In the past 12 months, when you take your HIV medications, how often do you take all the
medications you’re supposed to?” from self-report questionnaires for comparison (possible answers:
never, some, about half, most of the time, all of the time). In their self-report data, VACS did not ask a
question using the visual analogue scale, so we were unable to calculate percentage adherence.
3. Results
Adherence data were available on 11,689 patients: 7156 from the four cohorts with pharmacy data,
and 4533 from the four cohorts with self-report data. Table 1 shows characteristics of patients at the
time of ART initiation, overall and by cohort. The majority were male (83.9%) and the median age was
41 years. Median CD4 count and viral load at ART start were 200 cells/mm3 and 4.9 log10 copies/mL,
respectively. VACS and HAVACS are cohorts of military veterans, most of whom are men and were
older, on average. The distribution of risk groups for HIV acquisition also differs between cohorts:
VACS has poorly recorded transmission risk in their cohort and HOMER has a high proportion of
injection drug users (IDU) and patients with unknown transmission risk. Three out of eight cohorts
supplied refill drugs automatically without the patient requesting it.
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Table 1. Baseline patient and cohort characteristics, N = 11,689.
Pharmacy refills Self-Report
Characteristic N (%) Alberta HOMER VACS HAVACS ICONA Washington SHCS UAB
Total, N (%) 1,1689 485 (4.2) 2241 (19.2) 4404 (37.8) 26 (0.2) 203 (1.7) 198 (1.7) 3607 (30.9) 525 (4.5)
Female, N (%) 1883 (16.1) 97 (20.0) 386 (17.2) 111 (2.5) 0 (0) 42 (20.7) 29 (14.7) 1114 (30.9) 104 (19.8)
Age (median, IQR) 41 (34–49) 38 (32–44) 40 (33–47) 46 (39–52) 43 (39–50) 37 (32–43) 37 (31–44) 37 (31–44) 37 (29–45)
Transmission risk group
MSM 2667 (22.8) 235 (48.5) 494 (22.0) 66 (1.5) 11 (42.3) 67 (33.0) 100 (50.5) 1384 (38.4) 310 (59.1)
IDU 1824 (15.6) 73 (15.1) 796 (35.5) 574 (13.0) 6 (23.1) 41 (20.2) 52 (26.3) 263 (7.3) 19 (3.6)
Heterosexual 2291 (19.6) 167 (34.4) 164 (7.3) 7 (0.2) 2 (7.7) 85 (41.9) 0 (0) 1671 (46.3) 195 (37.1)
Blood 107 (0.9) 7 (1.4) 0 (0) 24 (0.5) 0 (0) 0 (0) 46 (23.2) 30 (0.8) 0 (0)
Other/unknown 4800 (41.1) 3 (0.6) 787 (35.1) 3733 (84.8) 7 (26.9) 10 (4.9) 0 (0) 259 (7.2) 1 (0.2)
Median (IQR) CD4 count
(cells/mm3) 200 (80–320) 178 (69–281) 180 (80–300) 192 (61–333) 140 (54–280) 285 (178–375) 213 (72–271) 207 (104–315) 239 (62–358)
Median (IQR) viral load (log10
copies/mL) 4.9 (4.4–5.3) 4.8 (4.2–5.3) 5.0 (4.7–5.2) 4.9 (4.4–5.3) 4.8 (4.5–5.3) 4.8 (4.4–5.3) 5.1 (4.6–5.6) 4.9 (4.4–5.4) 4.9 (4.3-5.4)
AIDS at baseline 2711 (23.2) 121 (25.0) 405 (18.1) 1244 (28.3) 10 (38.5) 13 (6.4) 42 (21.2) 701 (19.4) 175 (33.3)
Mean (SD) % adherence, 88.7 (20.1) 89.5 (20.5) 85.2 (24.8) 80.8 (22.0) 80.3 (20.9) 97.4 (11.2) 94.9 (11.4) 99.0 (5.1) 94.1 (15.2)
Median (IQR) year of adherence
measurement 2003 (2000–2006 2006 (2005–2007) 2001 (1998–2004) 2000 (1998–2002) 2002 (2001–2005) 2010 (2009–2011) 2009 (2008–2010) 2004 (2003–2007) 2009 (2008–2011)
Number of sites in cohorts * 1 500 125 1 32 1 7 1
Location (regional or national
cohort?) Regional Regional National Regional National Regional National Regional
Is prescription filled at once or
with refills? Refills Refills Refills Refills Refills Refills Refills Refills
Is refill drug supplied
automatically without patient
requesting it?
No No No Yes Yes No No Yes if mail orderdrug
MSM: Men who have sex with men, IDU: Injection drug users. SD: standard deviation. IQR: Interquartile range. * July 2013.
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Figure 2 shows the distribution of adherence across the eight cohorts. In cohorts with self-report
data, most patients reported high levels of adherence in the previous 28 days (median 100%,
interquartile range (IQR): 100–100). In cohorts with pharmacy data, estimated adherence was much
more variable (median 94%, IQR: 72–100). In cohorts with self-report data, adherence takes a limited
number of values as patients are asked to mark adherence on a visual scale, rather than report a number.
     x FOR PEER REVIEW  7  5 
 
 
Figure 2 shows the distribution of adherence across the eight cohorts. In cohorts with self-report 
data, most patients reported high levels of adherence in the previous 28 days (median 100%, 
interquartile range (IQR): 100–100). In cohorts with pharmacy data, estimated adherence was much 
more variable (median 94%, IQR: 72–100). In cohorts with self-report data, adherence takes a limited 
number of values as patients are asked to mark adherence on a visual scale, rather than report a 
number.  
 
 
Figure 2. Distribution of percentage adherence in each cohort. 
J. Clin. Med. 2018, 7, 328 7 of 13
Table 2 shows levels of adherence by cohort, together with their associations with viral failure.
In cohorts with self-report data, 8.6% of patients had viral failure, compared with 31.9% in cohorts
with pharmacy data. Estimated levels of adherence were much greater for cohorts with self-report
than pharmacy refill data. For cohorts with pharmacy data, 9% of patients were in the “low” category,
49% in “medium” and 42% in “high”. For cohorts with self-report data, 8% of patients were in the
“low” category, 17% in “medium” and 75% in “high”.
Among cohorts with pharmacy data, estimated adherence was much lower in patients with
subsequent viral failure than in those who were suppressed. This pattern was not seen to the same
extent among cohorts with self-report data. Associations of adherence with viral failure were similar
for Alberta and HOMER, but weaker for VACS. For HAVACS, there was little evidence that adherence
was associated with viral failure, although associations were imprecisely estimated because the sample
size was small. Using adherence data pooled over all cohorts with pharmacy data, the odds ratios
(ORs) (95% CI) for viral failure in lower and medium, compared to higher adherence groups, were 26.1
(21.1–32.4) and 4.4 (3.9–5.0), respectively. After adjusting for baseline covariates, the ORs were 23.0
(18.4–28.8) and 3.8 (3.4–4.4), respectively. We also compared lower with medium levels of adherence.
Across all cohorts, there was strong evidence that lower adherence led to higher rates of viral failure
compared to medium adherence.
Among cohorts with self-report data, there was little evidence that medium level adherence was
associated with higher odds of viral failure. However, self-reported low adherence was associated
with higher odds of viral failure. Using adherence data pooled over all cohorts with self-report data,
the ORs (95% CI) for viral failure in lower and medium, compared to higher adherence groups, were
3.1 (2.4–4.2) and 1.2 (0.9–1.5), respectively. After adjusting for baseline covariates, the ORs were 3.2
(2.3–4.4) and 1.1 (0.8–1.5), respectively. As with pharmacy data, we also compared lower with medium
levels of adherence and, again, found that lower levels of adherence led to higher rates of viral failure
compared to medium adherence.
Figures 3 and 4 show that the AUROC varied greatly between cohorts, from 0.45 in HAVACS to
0.86 in Alberta. Overall, compared with self-report, pharmacy adherence data better discriminated
those patients with viral failure as they have a larger range of continuous adherence values, and hence
more points on the ROC curve. AUROCs were relatively consistent between cohorts using the same
type of adherence data, except there was no evidence that adherence predicted viral failure in the
HAVACS cohort.
Sensitivity Analyses
For cohorts with pharmacy data, there was weak evidence that age modified the effect of
adherence on failure (Web Table 1, see Supplementary Materials). Among patients aged ≥50 years,
there were less pronounced differences in the magnitudes of associations of low and medium levels of
adherence with viral failure than for younger patients. In sensitivity analyses defining viral failure as
>50 copies/mL, results were similar to the main analysis, but attenuated (Web Table 2).
When restricting to the most recent 5 years of data (2009–2013), data were only available from
the Alberta, ICONA, SHCS, UAB, and Washington cohorts. Most were cohorts with self-report data
and odds ratios were similar to those for cohorts with self-report data in the main analyses (Web
Table 3). Results of analyses restricted to those remaining on their first ART regimen at the time of
the outcome were similar to the main analyses (Web Table 4). We also considered whether restricting
pharmacy data to just 28 days of data (and 3 or 6 months) made results more similar to those from
self-reported adherence. As most prescriptions are filled for at least 28 days, there was little variability
in adherence when considering the data this way. When comparing pharmacy data over 3 and
6 months, the AUROCs improved as the time increased (Web Table 5). We assessed over-adherence
in the Alberta, VACS, and HAVACS cohorts, and found that results were similar after excluding
over-adherent patients.
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Table 2. Viral suppression and levels of adherence across cohorts. Odds ratios (OR) and 95% CI for associations of adherence with viral failure.
Pharmacy Refill Data Self-Report Data
Cohort Alberta (Canada) HOMER (Canada) VACS (USA) HAVACS (USA) ICONA (Italy) Washington(USA) SHCS (Switzerland) UAB (USA)
N 485 2241 4404 26 203 198 3607 525
% suppressed 89.3 73.7 63.0 61.5 95.6 95.0 91.7 86.9
Median (IQR) % adherence 100 (90–100) 100 (80–100) 89 (68–100) 85 (70–100) 100 (100–100) 99 (94–100) 100 (100–100) 99 (96–100)
Among those suppressed 100 (95–100) 100 (100–100) 94 (80–100) 85 (71–96) 100 (100–100) 99 (94–100) 100 (100–100) 99 (96–100)
Among those not suppressed 49 (27–89) 61 (33–88) 73 (52–92) 87 (70–100) 100 (95–100) 97 (90–100) 100 (98–100) 98 (91–100)
Proportion with ≥95% adherence 67% 62% 39% 38% 91% 74% 96% 81%
Proportion with 100% adherence 52% 60% 28% 27% 85% 36% 82% 37%
Adherence
Lower 6.4 10.6 9.0 7.7 12.3 31.3 4.3 22.3
Medium 36.9 29.1 60.7 65.4 2.5 32.3 13.3 40.7
Higher 56.7 60.3 30.3 26.9 85.2 36.4 82.4 37.0
OR (95% CI) lower † vs. higher 80.4 (27.8,233) 85.2 (55.6,131) 12.3 (9.42,16.1) 0.75 (0.03,17.5) 3.8 (0.9,16.3) 1.2 (0.3,4.9) 4.4 (3.0,6.4) 2.0 (1.1,3.8)
OR (95% CI) medium † vs. higher 5.9 (2.5,14.1) 10.5 (8.1,13.6) 2.6 (2.2,3.0) 0.3 (0.1,1.9) * 0.5 (0.1,3.1) 1.2 (0.8,1.7) 0.8 (0.4,1.5)
OR (95% CI) lower vs. medium 13.6 (5.7,32.3) 8.1 (5.4,12.1) 4.8 (3.7,6.1) 2.4 (0.1,46.4) * 2.1 (0.4,12.1) 3.7 (2.3,6.0) 2.5 (1.3,4.7)
Overall ORs
OR (95% CI) lower † vs. higher 26.13 (21.05, 32.42) 3.14 (2.36, 4.19)
OR (95% CI) medium † vs. higher 4.41 (3.88, 5.01) 1.15 (0.86, 1.53)
OR (95% CI) lower † vs. medium 5.92 (4.86, 7.23) 2.74 (1.91, 3.95)
Adjusted ORs
OR (95% CI) lower † vs. higher 23.04 (18.44, 28.78) 3.19 (2.31, 4.40)
OR (95% CI) medium † vs. higher 3.84 (3.36, 4.39) 1.08 (0.80, 1.46)
OR (95% CI) lower † vs. medium 5.73 (4.67, 7.04) 3.13 (2.13, 4.59)
* Predicts suppression perfectly; † For pharmacy data lower is <45% adherent, medium 45–99%, higher 100%. For self-report data lower is ≤95%, medium 96–99%, higher 100%.
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To compare self-report and pharmacy measures directly, we used data from 348 VACS patients.
Due to the way the self-report question was asked (see Methods section), we could not calculate
adherence percentage, and so had to use the raw data. As self-reported adherence increased, so did
the pharmacy adherence measure (Web Table 6, test for trend p < 0.001). We compared the associations
of pharmacy/self-report adherence measures with viral failure in 331 patients. Web Table 7 shows
AUROCs for both measures of adherence with viral failure were similar.
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4. Discussion
4.1. Main Results
We combined data from eight HIV cohort studies: four with adherence measured using patient
self-report and four using pharmacy refill data. There was heterogeneity between cohorts in both
levels of adherence and viral failure. Both self-report and pharmacy refill adherence data can be used
to predict viral failure and show evidence that increasing adherence decreases the risk of viral failure.
Pharmacy measures were much more strongly associated with viral failure than self-reported measures,
although this may be due, in part, to the longer time-frame used in the pharmacy data and the higher
% with viral failure in the pharmacy cohorts. When considering data from the VACS cohort, which
provided pharmacy and self-report measures, the strength of associations of the different measures
with viral failure were similar. To make full use of adherence data, there needs to be an awareness of
cohort-specific factors affecting adherence. For example, in the Alberta cohort, patients with very poor
adherence may have drugs stopped pending correction of underlying issues compromising adherence.
4.2. Context
Pharmacy refill and self-report are different tools for measuring adherence that have different
characteristics and uses [20]. Short-term self-reported adherence may provide a better snapshot of
recent adherence behaviour, which may be beneficial in clinic situations because it can potentially
identify inadequate adherence before viral loads have begun to climb. However, their modest
association with viral failure suggests that some non-adherent patients report that they are adherent.
By contrast, pharmacy refill data give a longer term picture of adherence that is more strongly related
to subsequent viral failure than self-reported adherence.
Advantages of pharmacy refill data include being inexpensive and immune to social desirability/
recall bias or tampering [8,11]. Such data usually [8,21], although not always [22], have at least
moderate correlations with virologic outcomes. Potential errors in adherence measure through
pharmacy refill may occur if periods of undersupply are compensated for by oversupply [21]. Further,
pharmacy refill records will not reflect patients obtaining medications through alternative sources,
such as free samples, family or friends, or other pharmacies, which may occur in the most vulnerable
patients [8]. These concerns are highlighted by studies that have described groups of patients who were
highly adherent as measured by pharmacy refill data, but did not achieve or maintain viral suppression,
and poorly adherent patients who maintained undetectable viral load [11,23]. Such problems are
unlikely to have occurred in our study, because other sources of obtaining treatment are limited.
Nonetheless, pharmacy refill data should be considered a measure of drug availability, or refill
compliance, rather than a direct measure of consumption and, therefore, we cannot draw strong
conclusions on levels of drug required for suppression. Further, medication is not always taken
correctly as prescribed. The meaning of pharmacy data may differ between clinics with a “push”
system (patients automatically get new medications when required) or those with a “pull” system
(patients have to request medications when required).
Self-reported adherence, in context of viral load monitoring, is commonly used in both clinical care
and research settings, because of its low respondent and staff burden, ease and speed of administration,
and low cost [8,24]. The real-time nature of self-report questionnaires may prompt discussions with
providers regarding reasons for poor adherence and potential solutions [8], which may explain the
lower discriminatory power of self-report data compared with pharmacy data. A systematic review
of 77 studies of self-reported adherence found it to be significantly correlated with viral load in 84%
of recall periods [24]. A meta-analysis that included 65 studies found that the odds of viral failure
were more than doubled in patients who self-reported inadequate or poor adherence compared with
good adherence [25]. However, a common finding is that self-report data are susceptible to recall
bias, inaccurate memory, and social desirability bias [24]. Collecting adherence data via self-report
questionnaires may be difficult, or impossible, in cognitively impaired individuals [24].
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Several studies have compared self-report to pharmacy refill, both among HIV-infected
individuals and other disease conditions, such as chronic obstructive pulmonary disease
medications [26]. Self-report has often performed poorly compared with pharmacy measures,
particularly in settings such as intervention trials [26], and where there are interviewer-based measures
of adherence. In these settings, there may be consequences to poor adherence, or increased pressure
to overreport adherence. Depending on how the measurements are done and in what patient
population, studies have found no relationship between self-report and pharmacy refill [27], or only
poor correlations [26]. Comparisons between studies with self-report measures can be difficult, due
to the lack of standardised instruments, including differences in the questions asked, the response
format, and the recall period. For example, some questionnaires ask patients to recall the last 3 days
and others ask patients to recall up to 28 days or more. The recommended recall period is 1 month [28].
Although, when we considered a recall period of 12 months in the VACS data, we observed a strong
correlation between this and the pharmacy measure.
4.3. Strengths and Weaknesses
We investigated how adherence to ART is measured across cohorts from two continents providing
routine clinical care in high-income settings. These data are representative of patients in usual clinical
care and, so, it is likely that our results are generalisable to other high-income settings. Our analyses
may be subject to a number of biases. We assumed that viral load measures should be done every
6 months: if a viral load measurement was not available within this time period, then we had to exclude
the patient from analyses. Thus, patients included in analyses may have been more adherent to care
than excluded patients. On the other hand, less adherent patients may have been monitored more
closely and, therefore, be more likely to be included. Questionnaires were not routinely administered
at regular time intervals and, therefore, it was not feasible to derive a 1-year self-report adherence
measure without heavily reducing the sample size or making strong assumptions about adherence in
the time between questionnaires. Association of adherence levels with viral failure may be different
for newer ART regimens which have longer half-lives.
5. Implications
Cohorts should consider carefully how best to collect and make use of adherence data for patient
care within their healthcare setting. Pharmacy refill data require time and effort for their management,
but provided a better tool, than self-report data, for predicting viral failure in our study. Harmonisation
of pharmacy refill data management should be attempted in order to ensure that we are using the
same tools. Without this, we need to recognise that differences in dispensing will influence refill
data. Refill data are not as useful as self-report data in facilitating immediate interventions to change
behaviour, which may prevent patients from experiencing subsequent viral failure.
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